Corvus Pharmaceuticals. has been granted a patent for methods to treat various cancers using an adenosine-A2A receptor antagonist, alone or in combination with a PD-1 signaling pathway inhibitor. The patent includes specific pharmaceutical compositions and dosing regimens for effective cancer treatment. GlobalData’s report on Corvus Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Corvus Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Corvus Pharmaceuticals's grant share as of July 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.
Cancer treatment using a2a receptor antagonists and pd-1 inhibitors
The granted patent US12023337B2 outlines a method for treating various types of cancer through the administration of a specific pharmaceutical composition. The primary active ingredient is 7-(5-methylfuran-2-yl)-3-[[6-[[(3S)-oxolan-3-yl]oxymethyl]pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-5-amine, which is administered at a dosage of 100 mg twice daily. The method is applicable to a range of cancers, including lymphoma, colon cancer, lung cancer (specifically non-small cell lung cancer), triple negative breast cancer, melanoma, head and neck cancer, prostate cancer, bladder cancer, colorectal cancer, and renal cancer. The claims also specify that the composition can be administered orally and may include a pharmaceutically acceptable excipient.
Further claims detail variations in the treatment regimen, including alternative dosages of 200 mg per day, either as a single dose or divided into two doses. The patent emphasizes the versatility of the treatment method across different cancer types, with specific claims focusing on renal cancer and other malignancies. The administration method and dosage flexibility are designed to optimize therapeutic outcomes for patients in need of cancer treatment, highlighting the potential for this pharmaceutical composition to address multiple cancer indications effectively.
To know more about GlobalData’s detailed insights on Corvus Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
